Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.

Cell 2018 11 25;175(5):1244-1258.e26. Epub 2018 Oct 25.

Fels Institute for Cancer Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA. Electronic address:

Cyclin-dependent kinase 9 (CDK9) promotes transcriptional elongation through RNAPII pause release. We now report that CDK9 is also essential for maintaining gene silencing at heterochromatic loci. Through a live cell drug screen with genetic confirmation, we discovered that CDK9 inhibition reactivates epigenetically silenced genes in cancer, leading to restored tumor suppressor gene expression, cell differentiation, and activation of endogenous retrovirus genes. CDK9 inhibition dephosphorylates the SWI/SNF protein BRG1, which contributes to gene reactivation. By optimization through gene expression, we developed a highly selective CDK9 inhibitor (MC180295, IC50 = 5 nM) that has broad anti-cancer activity in vitro and is effective in in vivo cancer models. Additionally, CDK9 inhibition sensitizes to the immune checkpoint inhibitor α-PD-1 in vivo, making it an excellent target for epigenetic therapy of cancer.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00928674183126
Publisher Site
http://dx.doi.org/10.1016/j.cell.2018.09.051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247954PMC
November 2018
84 Reads
32.242 Impact Factor

Publication Analysis

Top Keywords

cdk9 inhibition
12
reactivates epigenetically
8
epigenetically silenced
8
genes cancer
8
gene expression
8
silenced genes
8
cdk9
6
cancer models
4
expression cell
4
suppressor gene
4
differentiation activation
4
effective in vivo
4
endogenous retrovirus
4
activation endogenous
4
in vivo cancer
4
tumor suppressor
4
cell differentiation
4
leading restored
4
discovered cdk9
4
confirmation discovered
4

Similar Publications